FDA Approves Pfizer and Arvinas’ Breast Cancer Drug for Specific Subtype
The US FDA approved Pfizer and Arvinas' breast cancer drug for a specific subtype patients, authorizing its commercial use in the United States. The decision enables Pfizer to expand its oncology portfolio with this novel targeted therapy.
1. FDA Approval Details
Pfizer and Arvinas secured FDA approval for their jointly developed breast cancer therapy, marking a regulatory milestone for the collaboration. The approval covers adult patients with a defined cancer subtype, clearing the way for labeling, pricing negotiations and commercial manufacturing preparations ahead of launch.
Related News
MS
Morgan Stanley to Co-Lead SpaceX’s $1.75T Nasdaq IPO with Four Banks
MS•
NVDA
Nvidia Posts 85% Revenue Surge to $81.6B, Forecasts $91B Next Quarter
NVDA•
BLTE
Belite Bio Begins FDA NDA Rolling Submission, Q1 Loss Widens on $15.7M R&D
BLTE•
AAPL
Apple App Store Blocks 1 Billion Fake Accounts, Prevents $2.2B Fraud
AAPL•
TJX
TJX Beats Q1 EPS by $0.20, Comps Up 6% and Spain Store Launch
TJX•
Sources
FRB